CagriSema vs Wegovy: How the Combo Compares to Semaglutide Alone

CagriSema takes Wegovy’s active ingredient and adds a second drug to it, and the result is more weight loss, though at the cost of somewhat more side effects and, for now, no availability. Wegovy is semaglutide alone; CagriSema is that same semaglutide combined with cagrilintide (an amylin drug). In trials the combination produced about 22.7% weight loss versus roughly 15% for semaglutide alone. But Wegovy is approved and available today, while CagriSema is still investigational. Here’s the full comparison.

The Relationship Between Them

This comparison is unusual because CagriSema literally contains Wegovy’s active ingredient. Wegovy is semaglutide 2.4 mg, a GLP-1 drug. CagriSema pairs that same semaglutide with cagrilintide, a long-acting amylin analog. So CagriSema isn’t a rival ingredient to Wegovy so much as Wegovy plus an extra mechanism. The added amylin component works through a different pathway (promoting fullness via a separate hormone system), and the idea is that two appetite-regulating drugs together produce more weight loss than one.

Head to Head

Here’s how they compare.

Weight Loss: The Combo Pulls Ahead

Adding cagrilintide clearly boosts the effect. In its REDEFINE 1 trial, CagriSema produced about 22.7% average weight loss over 68 weeks. Semaglutide alone, in its pivotal STEP 1 trial published in the New England Journal of Medicine in 2021, produced about 15% over a similar period. That’s a meaningful jump, roughly 7 percentage points more weight loss from adding the second drug. For someone who has plateaued on semaglutide alone, the combination’s extra mechanism is the appeal.

The Trade-Offs

More weight loss comes with more to consider. CagriSema tends to produce somewhat higher rates of gastrointestinal side effects (nausea, vomiting) than semaglutide alone, since it’s two appetite-regulating drugs rather than one, though most side effects in the trials were mild to moderate and improved over time. And crucially, CagriSema isn’t available: it’s investigational, with FDA review pending, while Wegovy is approved and has an established track record. Consider a hypothetical patient weighing the two: the combination offers more weight loss on paper, but it’s not something they can get yet, whereas Wegovy is proven and available now.

Availability: Wegovy’s Advantage

This is the decisive practical point. Wegovy is FDA approved and widely available, including as an option through telehealth services. CagriSema, despite its stronger trial numbers, remains investigational and accessible only through clinical trials. So while CagriSema may eventually offer more weight loss, Wegovy is the option people can actually use today.

What This Means for You Right Now

CagriSema is not available, and TrimRx does not offer it. Wegovy, on the other hand, is among the brand medications TrimRx offers, alongside compounded semaglutide and compounded tirzepatide and other brand GLP-1 options like Ozempic, Mounjaro, and Zepbound. If you want strong, proven weight loss you can start now, semaglutide-based treatment is available, while CagriSema remains a future prospect.

Frequently Asked Questions

Is CagriSema better than Wegovy?

On weight loss, CagriSema produced more in trials (about 22.7% versus roughly 15% for Wegovy), because it adds cagrilintide to semaglutide. But it also tends to cause more side effects and, importantly, isn’t available yet, while Wegovy is approved and proven. So “better” depends on whether you prioritize peak results or actual availability.

What does CagriSema add to Wegovy’s ingredient?

CagriSema contains the same semaglutide as Wegovy, plus cagrilintide, a long-acting amylin drug that promotes fullness through a different pathway. Combining the two hormone mechanisms produces more weight loss than semaglutide alone.

Can I get CagriSema instead of Wegovy?

No. CagriSema is investigational and available only through clinical trials. Wegovy is FDA approved and available, and it’s among the brand options TrimRx offers.

To focus on what you can actually start with today, you can explore the options available to you now with a licensed provider.

This information is for educational purposes and is not medical advice. CagriSema is investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.